Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1bMgpegj
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Mar 2023 – Oct 2024Where it's discussed
-
X / Twitter74 posts
-
News39 articles
-
YouTube3 videos
-
Facebook3 posts
-
Blogs3 articles
-
Bluesky1 posts
AI synopsis
What people are saying
Several discussions around the publication point to the lack of efficacy of nicotinamide, using phrases like 'null result' and 'did not lead to lower numbers,' which illustrate disappointment. The critical tone and repeated emphasis on the study's shortcomings showcase a collective skepticism about the potential benefits of nicotinamide, which greatly influences the overall sentiment.
Many posts express skepticism about the effectiveness of nicotinamide for skin cancer prevention, indicating a lack of consensus on the findings.
While some users show interest in the results, the tone is largely critical or dismissive, indicating limited intrigue.
Most discussions are superficial, with few engaging deeply with the research methodology or implications for practice.
The overall sentiment indicates that contributors see the results as having minimal significance for future treatment or research.
Abstract in brief
- Organ transplant recipients have a higher risk of skin cancer, and nicotinamide (vitamin B) is thought to help by repairing UV-induced DNA damage and reducing skin cancer incidence.
- A phase 3 trial assigned participants with a history of keratinocyte cancers to receive either 500 mg of nicotinamide or a placebo daily for 12 months, monitoring for new skin lesions during this period.
- Results showed no significant difference between the nicotinamide and placebo groups in the number of new keratinocyte cancers, suggesting that oral nicotinamide may not be effective in preventing skin cancer in organ transplant recipients.
Top posts
Most liked on X and BlueskyIn this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. @NEJM #MedEd #MedTwitter https://t.co/IiZnp6GrhF https://t.co/ScUnnFHb34
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/6WIbTocKXR https://t.co/OMOIpG08pB
In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for 12 months did not lead to lower numbers of keratinocyte cancers or actinic keratoses. https://t.co/JjLlBvaKHr https://t.co/v7E9yGOi49
Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32Va https://t.co/lk59Q1ugFA
All mentions
Your Skin Smoother & Younger Appearing With 3 Science-backed Supplements for Everyone #antiaging
Nicotinamide: Impact on Skin Health and Aging Prevention
Scientists Reveal Top Supplements to Improve Aging Skin Effectively
Defy skin aging with scientifically supported supplements. Dr. Brad Stanfield recommends three supplements based on the latest research to enhance skin health, reduce wrinkles, and promote longevity.
Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic https://t.co/QiGT1majer
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/kemLxfg76f
@LOrealParisTH #แชร์ได้ชัวร์ อ้างอิงแล้ว
Nicotinamide for Skin Cancer Chemoprevention in Transplant Recipients | PracticeUpdate https://t.co/KRKl2ySEbv
Dr Nicholas Allen gave a fascinating talk on #Nicotinamide for skin cancer prevention in transplant recipients @DermatologyACD - 60% of this high risk group had not used sunscreen in one of the study weeks!
#Nicotinamide for Skin-Cancer #Chemoprevention in Transplant #Recipients Clik here for more: https://t.co/XDV9RLdivg
Nicotinamide for Skin Cancer Chemoprevention in Transplant Recipients | comment: Sara Harcharik Perkins MD https://t.co/stolBGSk8a via @practiceupdate
#Nicotinamide for Skin-Cancer #Chemoprevention in Transplant Recipients https://t.co/XDV9RLcKFI
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
Congratulations to A/Prof Alvin Chong, Dr Edward Upjohn and colleagues on having their paper ‘Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients’ published in The New England Journal of Medicine. Visit the link below https://t.co/6kha5sfx9V https://t.co/eBM1pHh7WE
https://t.co/ak7EyrWgO8
RT @kidney_boy: Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
RT @kidney_boy: Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/hC1s6LBQin
RT @kidney_boy: Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
RT @kidney_boy: Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
RT @kidney_boy: Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://t.co/R1RCPHZcm0
Vitamin B3 for the prevention of skin cancer in transplant patients? Nope. https://www.nejm.org/doi/full/10.1056/NEJMoa2203086
How many authors does it take to publish a ssimple placebovs agent study on 158 participants? If it’s in NEJM, then climb aboard the authorship train! This study is crappy too: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/MKZFQiMxIk
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/yoOJNiYGOY
"Daily Treatment With Nicotinamide Does Not Reduce Risk Of Non-Melanoma Skin Cancer In Solid-Organ Transplant Recipients Who Have A History Of Skin Cancer." - in @NEJM
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/vM28qzJarK
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
RT @medical_xpress: Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32V…
Null result in #nicotinamide (vitamin B3) #skincancer trial of organ-transplant recipients @nejm https://t.co/BREeZM32Va https://t.co/lk59Q1ugFA
RT @imedverse: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers…
https://t.co/0jO2fmYOS5
In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. @NEJM #MedEd #MedTwitter https://t.co/IiZnp6GrhF https://t.co/ScUnnFHb34
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
RT @NEJM: Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1b…
Research Summary: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/JjLlBvaKHr https://t.co/oA1bMgpegj
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
“oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients” Nicotina mide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/ZxX3hWhobY
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/oSJRpMmENN
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/5NijUQI7Gv
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/uyHCYE140T @AADskin @AST_info
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
RT @NEJM: In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for…
In a placebo-controlled trial involving immunosuppressed organ-transplant recipients, oral nicotinamide (500 mg twice daily) for 12 months did not lead to lower numbers of keratinocyte cancers or actinic keratoses. https://t.co/JjLlBvaKHr https://t.co/v7E9yGOi49
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/AN1fTTKN12
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. https://t.co/m7vS6xHPp4
#Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. #dermaworld #skincare #research #vitaminB12 Submissions for the upcoming issue are opened. For any queries, please contact- skincare@escientificjournals.com For more details visit: https://t.co/3MUAZO0hoA
RT @hagsie: In this #RCT we found #nicotinamide did not reduce #SkinCancers in #TransplantRecipients @NEJM - have listen to the short-ta…
Echec de la vitamine B3 en prévention des cancers de la peau chez les personnes greffées avec antécédents https://t.co/jGrdjfcnQn https://t.co/p7ZLECp8KE
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/6GEVwseces
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients | NEJM https://t.co/VibkFMoUkb
RT @agingdoc1: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/6WIbTocKXR https://t.co/OMOIpG08pB
RT @agingdoc1: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/6WIbTocKXR https://t.co/OMOIpG08pB
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/6WIbTocKXR https://t.co/OMOIpG08pB
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/kA2zicPwMo
In this #RCT we found #nicotinamide did not reduce #SkinCancers in #TransplantRecipients @NEJM - have listen to the short-take recording https://t.co/HGn9GP14Ve @janette_vardy
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/0EnfjcXmiI https://t.co/SICF3fg00t